Abstract
Despite advances in diagnostic and therapeutic methods, gastrointestinal (GI) cancers have both a high incidence and a high mortality rate. In addition to surgery, chemotherapy and radiotherapy, novel modalities such as immunotherapy are increasingly used in the treatment of these cancers. However, the prognosis in GI cancers remains poor despite the availability of these treatments, which prompted the search for new prognostic and predictive markers. High-mobility group box-1 (HMGB1) is a non-histone DNA protein which is known as a nuclear transcription factor. The search for new therapeutic targets has also gained importance. In this review, the prognostic and predictive role of HMGB1 in gastrointestinal cancers will be discussed in light of current literature.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Archives of Medical Science – Civilization Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
